252 related articles for article (PubMed ID: 16434383)
21. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
23. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
García-Sanz R; Hernández JM; Sureda A; García-Laraña J; Prósper F; Alegre A; Bárez A; Mateos MV; San Miguel JF
Hematol Oncol; 2006 Dec; 24(4):205-11. PubMed ID: 17006969
[TBL] [Abstract][Full Text] [Related]
25. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
26. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
27. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone).
Hütter G; Szélenyi H; Schmittel A; Siehl JM; Thiel E; Keilholz U
Hematol Oncol; 2007 Sep; 25(3):132-9. PubMed ID: 17514772
[TBL] [Abstract][Full Text] [Related]
29. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G
J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952
[TBL] [Abstract][Full Text] [Related]
30. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Zimman R; Drake L; Riedel ER; Hedvat CV; Teruya-Feldstein J; Filippa DA; Fleisher M; Nimer SD; Comenzo RL
Br J Haematol; 2006 Jan; 132(2):155-61. PubMed ID: 16398649
[TBL] [Abstract][Full Text] [Related]
32. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
33. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
35. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
García-Sanz R; González-Porras JR; Hernández JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; López R; Grande-García C; Alegre A; Vargas-Pabón M; Gutiérrez ON; Rodríguez JA; San Miguel JF
Leukemia; 2004 Apr; 18(4):856-63. PubMed ID: 14973508
[TBL] [Abstract][Full Text] [Related]
36. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
37. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
38. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
[TBL] [Abstract][Full Text] [Related]
39. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
[TBL] [Abstract][Full Text] [Related]
40. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
Hovenga S; Daenen SM; de Wolf JT; van Imhoff GW; Kluin-Nelemans HC; Sluiter WJ; Vellenga E
Ann Hematol; 2005 May; 84(5):311-6. PubMed ID: 15605244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
